Publication date: Sep 18, 2023
COVID-19 vaccine was demonstrated to be effective in dialysis patients, but boosters are mandatory due to a rapid waning of anti-spike antibodies. A vaccination strategy based on immunologic response might be useful to maintain a favorable risk-benefit balance in this vulnerable population. CoviDial is an observational prospective study enrolling 121 dialysis patients to receive a 3-dose mRNA-1273 vaccine according to a uniform schedule. At baseline, months 1, 3, 6, 9, and 12, anti-spike antibodies against four epitopes (S1, S2, ECD-S1 + S2, RBD) were monitored with a multiplex immunodot enzymatic assay. Potential correlation between initial serologic response and subsequent COVID-19 infection was then assessed. Overall, 96. 2% and 96. 8% of patients had anti-RBD antibodies at 3 and 12 months, respectively. All antibodies titers significantly decreased at month 6 compared to month 3. Booster vaccine induced a robust serologic response at month 9, but with a waning 3 months later, particularly for anti-S2 (37. 2 +/- 3. 3 vs. 61. 3 +/- 3. 0, p
| Concepts | Keywords |
|---|---|
| 3months | Anti |
| Dialysis | Antibodies |
| Effective | Based |
| Vaccine | Covid |
| Dialysis | |
| Immunodot | |
| Month | |
| Multiplex | |
| Rbd | |
| S2 | |
| Serologic | |
| Spike | |
| Vaccination | |
| Vaccine | |
| Waning |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | VO | vaccination |
| disease | VO | COVID-19 vaccine |
| disease | VO | effective |
| drug | DRUGBANK | Isoxaflutole |
| disease | VO | population |
| disease | VO | dose |
| disease | VO | vaccine |
| disease | IDO | assay |
| disease | MESH | infection |